Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany.
- DOI
- 10.1007/s10198-017-0953-z
- Published
- 2019 Mar
- Container
- The European journal of health economics : HEPAC : health economics in prevention and care
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10198-017-0953-z,
title = {Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany.},
author = {Pöllinger B and Schmidt W and Seiffert A and Imhoff H and Emmert M},
year = {2019},
journal = {The European journal of health economics : HEPAC : health economics in prevention and care},
doi = {10.1007/s10198-017-0953-z},
url = {https://doi.org/10.1007/s10198-017-0953-z}
}RIS
TY - JOUR TI - Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany. AU - Pöllinger B AU - Schmidt W AU - Seiffert A AU - Imhoff H AU - Emmert M PY - 2019 JO - The European journal of health economics : HEPAC : health economics in prevention and care DO - 10.1007/s10198-017-0953-z UR - https://doi.org/10.1007/s10198-017-0953-z ER -
APA
B, P., W, S., A, S., H, I., & M, E. (2019). Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany.. The European journal of health economics : HEPAC : health economics in prevention and care. https://doi.org/10.1007/s10198-017-0953-z
Source records
- pubmed · retrieved 2026-09-26T14:57:51.777Z
- europe-pmc · retrieved 2026-09-26T14:57:51.773Z